Published:
The Lancet
Date:
Abstract:
Most patients with type 2 diabetes begin pharmacotherapy with metformin,
but eventually need additional treatment. We assessed the safety and
efficacy of once weekly exenatide, a glucagon-like peptide 1 receptor
agonist, versus maximum approved doses of the dipeptidyl peptidase-4
inhibitor, sitagliptin, or the thiazolidinedione, pioglitazone, in patients
treated with metformin.